Zai Lab Ltd Ordinary Shares 09688
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HK$20.64
- Day Range
- HK$19.06–19.91
- 52-Week Range
- HK$12.49–27.04
- Bid/Ask
- HK$19.56 / HK$19.65
- Shares Outstanding
- 1.12B
- Market Cap
- HK$22.06B
- Volume/Avg
- 2M / 8M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.51
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,784
- Website
- https://www.zailaboratory.com
Valuation
|
Metric
|
09688
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.87 |
Price/Sales | 6.51 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
09688
|
|---|---|
Quick Ratio | 1.61 |
Current Ratio | 2.13 |
Interest Coverage | −35.53 |
Quick Ratio
09688
Profitability
|
Metric
|
09688
|
|---|---|
Return on Assets (Normalized) | −13.93% |
Return on Equity (Normalized) | −22.33% |
Return on Invested Capital (Normalized) | −19.27% |
Return on Assets
09688
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%kn>MBT | LOCK|<<#! | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|KY$@yR | LOCK|?z#V | $76B | |||
| Moderna Inc
MRNA
| LOCK|f^$$DND | LOCK|xxj | $75B | |||
| argenx SE ADR
ARGX
| LOCK|?$$Fc<& | LOCK|!X$ | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|sN>?z!# | LOCK|By | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^v<^r& | LOCK|>$#yg | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&&%SsVFC | LOCK|?sbH | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|^V%L^d | LOCK|>? | $24B | |||
| Incyte Corp
INCY
| LOCK|NQGKbg$ | LOCK|PYX | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|m%%d#& | LOCK|#dx | $15B |
United States